News & Events
Drug Discovery Webinar 2022
When: Mar. 28th, 2022 to Mar. 30th, 2022
Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. has been invited to present, “mRNA translation monitoring as a new strategy in drug discovery,” during the Scholars International Webinar on Advances in Drug Discovery and Development on March 29th, 11:35-12:10 GMT. The Drug Discovery Webinar 2022 aims to bring together renowned researchers, scientists and scholars to exchange and share their experiences on all aspects of chemistry, drug discovery, and drug design with a focus on the latest advancements in the drug discovery and development process.
5th Annual Neuroscience Innovation Forum
When: Mar. 22nd, 2022 to Mar. 23rd, 2022
Our Co-Founder and CEO, Yochi Slonim will participate in a roundtable discussion during the 5th Annual Neuroscience Innovation Forum for Business Development, Licensing and Investment hosted virtually by Sachs Associates. The Industry Roundtable: Latest Trends in Partnering and M&A Panel will take place on March 22nd, 2022, 8:50 AM ET. The roundtable features executives from various pharmaceutical companies and will discuss the future of mergers and acquisitions in the biotech industry.
RNA-Based Drugs and Vaccines Innovation Summit
When: Mar. 12th, 2022
Anima Biotech’s CSO, Iris Alroy, Ph.D. has been invited to present at the RNA-Based Drugs and Vaccines Innovation Summit hosted by the International Science and Technology Conference Institute on March 12, 2022.
Through Reviewing the progress and achievements of RNA drugs, this forum will build a communication platform for scientific researchers and peers to deepen academic exchanges and industrialization discussion and promote the research and development of RNA drugs and vaccines.
15th Drug Discovery Innovation Program
When: Mar. 2nd, 2022
Anima Biotech’s CSO, Iris Alroy, Ph.D. will serve as chair and give a presentation titled, “Paving the Way-RNA Therapeutics on the Rise” on March 2, 2022, 14:35 CET, during the 15th Drug Discovery Innovation Program.
The event will focus on new technologies and innovative processes that are fundamentally changing what drug discovery research will look like in the next two to five years. This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on the adoption of technology to combat these.
3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
When: Feb. 22nd, 2022 to Feb. 24th, 2022
Anima Biotech’s CSO, Iris Alroy, Ph.D. has been invited to present on “Anima’s pan-KRAS mRNA translation modulators in mKRAS driven tumors” on February 24th 10:15 am EST with a live Q&A following the talk. The RAS/MAPK Pathway Target Drug Discovery Summit features 150+ experts in drug discovery, cancer biology, and medicinal chemistry, providing an exciting opportunity to learn more about the future of drugging the RAS/MAPK pathway and highlighting advancements in screening platforms, target identification, and emerging pipelines.
4th RNA-Targeted Drug Discovery Summit
When: Dec. 7th, 2021 to Dec. 9th, 2021
Anima Biotech has been invited to present an overview of its mRNA Lightning platform during the 4th annual RNA-Targeted Drug Discovery Summit. Anima Vice President of Research and Development, Iris Alroy, Ph.D. Will give a presentation titled, “Targeting mRNA Biology in a Tissue Selective & Disease-Specific Manner with Small Molecules” on Thursday, December 9th at 12:15 p.m. ET. In addition, Yochi Slonim, Co-founder and CEO of Anima Biotech will participate in a Fireside Chat & Networking Session titled, “Biopharma & Investment Partnering – Discussing the Future Landscape of Investment & Collaborations for RNA Small Molecule Space” on Thursday, December 9th at 1:30 p.m. ET. The session is dedicated to shining a spotlight onto the advantages and challenges of biopharma partnering and opening the floor to discussions with peers surrounding experiences with partnering and facilitating industry connections.
The 4th RNA-Targeted Drug Discovery Summit will be an opportunity for thought leaders and experts in the biology and chemistry of RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties. Over 150+ biopharmaceutical representatives will lead conversations showcasing techniques to successfully translate RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field.
Elrig UK’s Drug Discovery 2021
When: Oct. 19th, 2021 to Oct. 20th, 2021
Anima Biotech has been invited to present at Elrig UK’s Drug Discovery 2021 meeting, taking place in Liverpool, U.K. Iris Alroy, Ph.D., Vice President of Research and Development at Anima Biotech, will give a presentation titled, “mRNA Lightning platform for the discovery of selective small molecule mRNA regulatory drugs.” Elrig’s annual Drug Discovery meeting is one of Europe’s largest gatherings for life science industry professionals and serves as a platform for the whole drug discovery community to re-connect with colleagues, re-invent the process of drug discovery and re-imagine a new vision for drug discovery.
Industry (SCI)’s “RNA as a Target For The Life Sciences”
When: Oct. 12th, 2021 to Oct. 13th, 2021
Anima Biotech has been invited to present at SCI’s “RNA as a target for the life sciences” event, taking place virtually this year. Iris Alroy, Ph.D., Vice President of Research and Development at Anima Biotech, will give a presentation titled, “mRNA translation modulators binding to novel targets: from mRNA processing to mRNA translation”, followed by her participation in a panel. The event will feature global leaders and leading experts in RNA technology to discuss current and future aspects of this field. In addition to Anima’s presentation, Jason Tierney, Senior Medicinal Scientist of Anima Biotech, will be chairing sessions alongside some of the distinguished organizing committee members.
Sachs Associates 21st Annual Biotech in Europe Forum (BEF)
When: Oct. 7th, 2021 to Oct. 8th, 2021
Anima Biotech has been invited to participate during the virtual 21st Annual Biotech in Europe Forum (BEF) hosted by Sachs Associates. Yochi Slonim, Co-founder and CEO, will serve as an expert on the “Platform Technologies & Novel Therapeutics” panel. The event will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 15 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities.
UBS Biotechnology Private Company Symposium
When: Sep. 22nd, 2021
Anima Biotech has been invited to give a presentation during the UBS Biotechnology Private Company Symposium. Yochi Slonim, Co-founder and CEO, will provide a corporate update to those registered for the conference. At more than 300 conferences a year across Europe, Asia Pacific and the Americas, UBS connects corporate leaders and the global investor community, influential policy makers and industry experts. UBS’ award-winning analysts and economists debate the big ideas, trends and challenges shaping the environment, bringing attendees local knowledge with global perspective.